Basic and Clinical Immunology Relevant to Pediatric Rheumatic Disease
Innate and adaptive immunity
Pediatric rheumatic disease sits at the interface of innate activation and adaptive autoimmunity. Pattern-recognition receptors (TLRs, NOD-like receptors) sense microbial and endogenous danger signals, and the NLRP3 inflammasome cleaves pro-IL-1β into active IL-1β - the pathway driving systemic JIA, CAPS, and DIRA. Adaptive immunity adds antigen-specific responses: Th17/IL-23 pathways promote enthesitis and psoriasis, T follicular helper cells drive autoantibody production, and regulatory T cells maintain peripheral tolerance. Loss of tolerance through molecular mimicry, defective apoptotic debris clearance, or complement deficiency permits autoantibodies and immune-complex deposition.
Pathways and drugs
Map therapies to mechanisms: TNF inhibition, IL-1 blockade (anakinra, canakinumab), IL-6 blockade (tocilizumab), co-stimulation blockade (abatacept), BAFF blockade (belimumab), B-cell depletion (rituximab), and JAK-STAT inhibition. Type I interferon signatures characterize juvenile dermatomyositis and a subset of SLE. Complement cuts both ways: inherited early-complement deficiency predisposes to SLE and encapsulated infections, while low C3/C4 in active SLE usually reflects consumption.
Traps
A positive ANA is not a diagnosis; 10–20% of healthy children have low-titer ANA. HLA-B27 is a risk marker, not a diagnostic test. A normal CRP does not exclude active synovitis, and a high ESR may reflect anemia or recent IVIG rather than inflammation.
Worked rule
A toddler with daily spiking fevers, an evanescent rash, and markedly elevated CRP and ferritin points to IL-1-driven systemic inflammation; a dramatic response to anakinra supports that mechanism.